A Proteomic Platform Enables to Test for AML Normalization In Vitro

Samuel M. Meier-Menches; Benjamin Neuditschko; Lukas Janker; Marlene C. Gerner; Klaus G. Schmetterer; Albrecht Reichle; Christopher Gerner

doi:10.3389/fchem.2022.826346

A Proteomic Platform Enables to Test for AML Normalization In Vitro

Samuel M. Meier-Menches (Korresp. Autor*in)
, Benjamin Neuditschko
, Lukas Janker
, Marlene C. Gerner
, Klaus G. Schmetterer
, Albrecht Reichle
, Christopher Gerner (Korresp. Autor*in)

Veröffentlichungen: Beitrag in Fachzeitschrift › Artikel › Peer Reviewed

Originalsprache	Englisch
Aufsatznummer	826346
Seitenumfang	12
Fachzeitschrift	Frontiers in Chemistry
Jahrgang	10
DOIs	https://doi.org/10.3389/fchem.2022.826346
Publikationsstatus	Veröffentlicht - 1 Feb. 2022

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

ÖFOS 2012

106037 Proteomik

Zugriff auf Dokument

10.3389/fchem.2022.826346Lizenz: CC BY 4.0

https://phaidra.univie.ac.at/o:1660055Lizenz: CC BY 4.0

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Zitationsweisen

@article{07b917ba0c49433eace9dcbce42ed44c,

title = "A Proteomic Platform Enables to Test for AML Normalization In Vitro",

keywords = "AML-acute myeloid leukaemia, arsenic trioxide, cancer, differentiation, normalization, plecstatin-1, proteomics, Ruthenium, TRANS-RETINOIC ACID, ACUTE PROMYELOCYTIC LEUKEMIA, ACUTE MYELOID-LEUKEMIA, ARSENIC TRIOXIDE, DIFFERENTIATION THERAPY, CELLS, MECHANISMS, TARGET, ACTIVATION, EXPRESSION, AML—acute myeloid leukaemia",

author = "Meier-Menches, \{Samuel M.\} and Benjamin Neuditschko and Lukas Janker and Gerner, \{Marlene C.\} and Schmetterer, \{Klaus G.\} and Albrecht Reichle and Christopher Gerner",

note = "Accession Number: WOS:000756087000001 PubMed ID: 35178376",

year = "2022",

month = feb,

day = "1",

doi = "10.3389/fchem.2022.826346",

language = "English",

volume = "10",

journal = "Frontiers in Chemistry",

issn = "2296-2646",

publisher = "FRONTIERS MEDIA SA",

}

TY - JOUR

T1 - A Proteomic Platform Enables to Test for AML Normalization In Vitro

AU - Meier-Menches, Samuel M.

AU - Neuditschko, Benjamin

AU - Janker, Lukas

AU - Gerner, Marlene C.

AU - Schmetterer, Klaus G.

AU - Reichle, Albrecht

AU - Gerner, Christopher

N1 - Accession Number: WOS:000756087000001 PubMed ID: 35178376

PY - 2022/2/1

Y1 - 2022/2/1

KW - AML-acute myeloid leukaemia

KW - arsenic trioxide

KW - cancer

KW - differentiation

KW - normalization

KW - plecstatin-1

KW - proteomics

KW - Ruthenium

KW - TRANS-RETINOIC ACID

KW - ACUTE PROMYELOCYTIC LEUKEMIA

KW - ACUTE MYELOID-LEUKEMIA

KW - ARSENIC TRIOXIDE

KW - DIFFERENTIATION THERAPY

KW - CELLS

KW - MECHANISMS

KW - TARGET

KW - ACTIVATION

KW - EXPRESSION

KW - AML—acute myeloid leukaemia

UR - https://www.scopus.com/pages/publications/85124753969

U2 - 10.3389/fchem.2022.826346

DO - 10.3389/fchem.2022.826346

M3 - Article

C2 - 35178376

SN - 2296-2646

VL - 10

JO - Frontiers in Chemistry

JF - Frontiers in Chemistry

M1 - 826346

ER -

A Proteomic Platform Enables to Test for AML Normalization In Vitro

UN SDGs

ÖFOS 2012

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Zitationsweisen